STOCK TITAN

Cytokinetics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Negative)
Tags
conferences
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) will be participating in several investor conferences in November. The conferences include UBS BioPharma Conference, Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and 35th Annual Piper Sandler Healthcare Conference. Interested parties can access the live webcasts of the events on the Cytokinetics website.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in November:

  • UBS BioPharma Conference on Wednesday, November 8, 2023 at 1:00 PM Eastern Time in a fireside chat with Fady I. Malik, Executive Vice President of Research & Development, and Andrew Callos, Executive Vice President, Chief Commercial Officer, at the Fontainebleau Miami Beach in Miami Beach, FL.
  • Truist Securities BioPharma Symposium on Thursday, November 9, 2023 at 10:45 AM Eastern Time in a panel discussion, entitled “Muscle Matters: Innovative Approaches to Targeting Cardiac & Skeletal Muscle,” with Fady I. Malik, Executive Vice President of Research & Development, at the Lotte New York Palace in New York, NY.
  • Jefferies London Healthcare Conference Healthcare Conference 2023 on Tuesday, November 14, 2023 at 11:00 AM Greenwich Mean Time in a fireside chat with Robert I. Blum, President and Chief Executive Officer, at The Waldorf Hilton in London, England.
  • 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023 at 12:30 PM Eastern Time in a fireside chat with Robert I. Blum, President and Chief Executive Officer, and Fady I. Malik, Executive Vice President of Research & Development, at the Lotte New York Palace in New York, NY.

Interested parties may access the live webcasts of the fireside chats and panel discussion by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Aficamten is a next-in-class cardiac myosin inhibitor, currently the subject of three Phase 3 clinical trials: SEQUOIA-HCM, evaluating aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM), MAPLE-HCM, evaluating aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM and ACACIA-HCM, evaluating aficamten in patients with non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility, and CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF. In 2023, Cytokinetics is celebrating its 25-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757


FAQ

Which investor conferences will Cytokinetics be participating in November?

Cytokinetics will be participating in the UBS BioPharma Conference, Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and 35th Annual Piper Sandler Healthcare Conference.

Who will be representing Cytokinetics at these conferences?

Fady I. Malik, Executive Vice President of Research & Development, and Andrew Callos, Executive Vice President, Chief Commercial Officer, will be representing Cytokinetics at the UBS BioPharma Conference. Fady I. Malik, Executive Vice President of Research & Development, will be representing Cytokinetics at the Truist Securities BioPharma Symposium. Robert I. Blum, President and Chief Executive Officer, will be representing Cytokinetics at the Jefferies London Healthcare Conference. Robert I. Blum, President and Chief Executive Officer, and Fady I. Malik, Executive Vice President of Research & Development, will be representing Cytokinetics at the 35th Annual Piper Sandler Healthcare Conference.

Where will these conferences take place?

The UBS BioPharma Conference will take place at the Fontainebleau Miami Beach in Miami Beach, FL. The Truist Securities BioPharma Symposium will take place at the Lotte New York Palace in New York, NY. The Jefferies London Healthcare Conference will take place at The Waldorf Hilton in London, England. The 35th Annual Piper Sandler Healthcare Conference will take place at the Lotte New York Palace in New York, NY.

How can interested parties access the webcasts of the events?

Interested parties can access the live webcasts of the events by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com.

How long will the webcast replays be available?

The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the events.

Cytokinetics Inc.

NASDAQ:CYTK

CYTK Rankings

CYTK Latest News

CYTK Stock Data

5.80B
115.63M
0.53%
118.71%
12.36%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO